Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Common Equity (2017 - 2025)

Puma Biotechnology's Common Equity history spans 9 years, with the latest figure at $130.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 41.48% year-over-year to $130.3 million; the TTM value through Dec 2025 reached $130.3 million, up 41.48%, while the annual FY2025 figure was $130.3 million, 41.48% up from the prior year.
  • Common Equity reached $130.3 million in Q4 2025 per PBYI's latest filing, up from $115.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $130.3 million in Q4 2025 to a low of -$10.9 million in Q3 2021.
  • Average Common Equity over 5 years is $48.1 million, with a median of $34.6 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 2311.04% in 2021, then surged 983.4% in 2022.
  • A 5-year view of Common Equity shows it stood at -$2.4 million in 2021, then soared by 983.4% to $21.6 million in 2022, then surged by 147.33% to $53.4 million in 2023, then surged by 72.38% to $92.1 million in 2024, then surged by 41.48% to $130.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Common Equity are $130.3 million (Q4 2025), $115.3 million (Q3 2025), and $104.7 million (Q2 2025).